Related Experiment Video
Updated: May 16, 2026
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
Published on: August 29, 2016
Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer
Roberta Ferraldeschi1, Gerhardt Attard, Johann S de Bono
1Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.
Background:
Major advances in our understanding of the underlying biology of prostate cancer have helped to herald a new era in the treatment of castration-resistant prostate cancer (CRPC), with 5 new agents having shown a survival advantage in the last 3 years and an impressive number of promising novel agents now entering the clinic.
Content:
We discuss the challenges facing drug development for CRPC and strategies to meet these challenges, with a focus not only on the development of predictive and intermediate endpoint biomarkers, but also on novel hypothesis-testing, biomarker-driven clinical trial designs.
Summary:
With several promising agents now entering the clinic, there is increasing pressure to rethink drug development for CRPC to ensure that novel agents are appropriately evaluated and that patients and resources are appropriately allocated. We envision that biomarker-driven, reiterative clinical trials will have a major impact on CRPC treatment through the testing of robust scientific hypotheses with rationally designed drugs and drug combinations administered to selected patients.
Insights
Advances in prostate cancer biology have led to new treatments for castration-resistant prostate cancer (CRPC). Future drug development will focus on biomarker-driven trials to optimize patient selection and resource allocation for novel agents.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Significant progress in understanding prostate cancer biology.
- Emergence of a new era in castration-resistant prostate cancer (CRPC) treatment.
- Five new agents demonstrating survival benefits in CRPC within three years.
Purpose of the Study:
- To discuss challenges in CRPC drug development.
- To outline strategies for overcoming these challenges.
- To emphasize the role of biomarkers and novel trial designs.
Main Methods:
- Review of current challenges in CRPC drug development.
- Focus on predictive and intermediate endpoint biomarkers.
- Exploration of novel hypothesis-testing and biomarker-driven clinical trial designs.
Main Results:
- Several promising novel agents are entering clinical trials for CRPC.
- There is a growing need to re-evaluate CRPC drug development strategies.
- Ensuring appropriate evaluation of novel agents and optimal resource allocation is critical.
Conclusions:
- Biomarker-driven, reiterative clinical trials are envisioned to significantly impact CRPC treatment.
- These trials will test scientific hypotheses with rationally designed drugs and drug combinations.
- Targeted patient selection will be key for effective CRPC therapy.
More Related Videos
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Related Concept Videos
01:26Drug Discovery: Overview
01:28Preclinical Development: Overview